A guaranteed income intervention to improve the health and financial well-being of low-income black emerging adults: study protocol for the Black Economic Equity Movement randomized controlled crossover trial.
Black young adult
cash transfer
cross-over trial
economic empowerment
guaranteed income
socioeconomic disparities in health
systemic racism
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
08
2023
accepted:
19
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Economic inequity systematically affects Black emerging adults (BEA), aged 18-24, and their healthy trajectory into adulthood. Guaranteed income (GI)-temporary, unconditional cash payments-is gaining traction as a policy solution to address the inequitable distribution of resources sewn by decades of structural racism and disinvestment. GI provides recipients with security, time, and support to enable their transition into adulthood and shows promise for improving mental and physical health outcomes. To date, few GI pilots have targeted emerging adults. The BEEM trial seeks to determine whether providing GI to BEA improves financial wellbeing, mental and physical health as a means to address health disparities. Using a randomized controlled crossover trial design, 300 low-income BEA from San Francisco and Oakland, California, are randomized to receive a $500/month GI either during the first 12-months of follow-up (Phase I) or during the second 12-months of a total of 24-months follow-up (Phase II). All participants are offered enrollment in optional peer discussion groups and financial mentoring to bolster financial capability. Primary intention-to-treat analyzes will evaluate the impact of GI at 12 months among Phase I GI recipients compared to waitlist arm participants using Generalized Estimating Equations (GEE). Primary outcomes include: (a) financial well-being (investing in education/training); (b) mental health status (depressive symptoms); and (c) unmet need for mental health and sexual and reproductive health services. Secondary analyzes will examine effects of optional financial capability components using GEE with causal inference methods to adjust for differences across sub-strata. We will also explore the degree to which GI impacts dissipate after payments end. Study outcomes will be collected via surveys every 3 months throughout the study. A nested longitudinal qualitative cohort of 36 participants will further clarify how GI impacts these outcomes. We also discuss how anti-racism praxis guided the intervention design, evaluation design, and implementation. Findings will provide the first experimental evidence of whether targeted GI paired with complementary financial programming improves the financial well-being, mental health, and unmet health service needs of urban BEA. Results will contribute timely evidence for utilizing GI as a policy tool to reduce health disparities. https://clinicaltrials.gov, identifier NCT05609188.
Sections du résumé
Background
UNASSIGNED
Economic inequity systematically affects Black emerging adults (BEA), aged 18-24, and their healthy trajectory into adulthood. Guaranteed income (GI)-temporary, unconditional cash payments-is gaining traction as a policy solution to address the inequitable distribution of resources sewn by decades of structural racism and disinvestment. GI provides recipients with security, time, and support to enable their transition into adulthood and shows promise for improving mental and physical health outcomes. To date, few GI pilots have targeted emerging adults. The BEEM trial seeks to determine whether providing GI to BEA improves financial wellbeing, mental and physical health as a means to address health disparities.
Methods/design
UNASSIGNED
Using a randomized controlled crossover trial design, 300 low-income BEA from San Francisco and Oakland, California, are randomized to receive a $500/month GI either during the first 12-months of follow-up (Phase I) or during the second 12-months of a total of 24-months follow-up (Phase II). All participants are offered enrollment in optional peer discussion groups and financial mentoring to bolster financial capability. Primary intention-to-treat analyzes will evaluate the impact of GI at 12 months among Phase I GI recipients compared to waitlist arm participants using Generalized Estimating Equations (GEE). Primary outcomes include: (a) financial well-being (investing in education/training); (b) mental health status (depressive symptoms); and (c) unmet need for mental health and sexual and reproductive health services. Secondary analyzes will examine effects of optional financial capability components using GEE with causal inference methods to adjust for differences across sub-strata. We will also explore the degree to which GI impacts dissipate after payments end. Study outcomes will be collected via surveys every 3 months throughout the study. A nested longitudinal qualitative cohort of 36 participants will further clarify how GI impacts these outcomes. We also discuss how anti-racism praxis guided the intervention design, evaluation design, and implementation.
Discussion
UNASSIGNED
Findings will provide the first experimental evidence of whether targeted GI paired with complementary financial programming improves the financial well-being, mental health, and unmet health service needs of urban BEA. Results will contribute timely evidence for utilizing GI as a policy tool to reduce health disparities.
Clinical trial registration
UNASSIGNED
https://clinicaltrials.gov, identifier NCT05609188.
Identifiants
pubmed: 38026401
doi: 10.3389/fpubh.2023.1271194
pmc: PMC10658785
doi:
Banques de données
ClinicalTrials.gov
['NCT05609188']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1271194Informations de copyright
Copyright © 2023 Lippman, Libby, Nakphong, Arons, Balanoff, Mocello, Arnold, Shade, Qurashi, Downing, Moore, Dow and Lightfoot.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Psychol Sci Public Interest. 2011 Aug;12(2):57-91
pubmed: 26167708
AIDS Behav. 2017 Jul;21(7):2156-2166
pubmed: 27544516
Am J Epidemiol. 2004 Aug 1;160(3):230-9
pubmed: 15257996
Stat Med. 2009 Aug 15;28(18):2338-55
pubmed: 19472307
Health Serv Res. 2013 Feb;48(1):129-49
pubmed: 22716901
Int J Behav Med. 2008;15(3):194-200
pubmed: 18696313
Soc Sci Med. 2019 Apr;226:225-235
pubmed: 30674436
Cultur Divers Ethnic Minor Psychol. 2008 Oct;14(4):297-306
pubmed: 18954165
JAMA. 2000 May 17;283(19):2579-84
pubmed: 10815125
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Ann N Y Acad Sci. 2010 Feb;1186:5-23
pubmed: 20201865
Child Health Care. 1992 Fall;21(4):233-8
pubmed: 10122432
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Am Psychol. 2000 May;55(5):469-80
pubmed: 10842426
Gen Hosp Psychiatry. 2017 May;46:14-19
pubmed: 28622809
Psychol Methods. 2002 Jun;7(2):147-77
pubmed: 12090408
J Adolesc Health. 2010 Mar;46(3 Suppl):S75-91
pubmed: 20172462
J Consult Clin Psychol. 1974 Dec;42(6):861-5
pubmed: 4436473
BMC Public Health. 2016 Nov 25;16(1):1191
pubmed: 27884181
Lancet Glob Health. 2016 Dec;4(12):e978-e988
pubmed: 27815148
J Health Soc Behav. 1997 Mar;38(1):21-37
pubmed: 9097506
Soc Psychiatry Psychiatr Epidemiol. 2013 Oct;48(10):1555-67
pubmed: 23385803
Am Econ J Appl Econ. 2010 Jan;2(1):86-115
pubmed: 20582231
Biometrics. 2001 Mar;57(1):120-5
pubmed: 11252586
Am J Public Health. 2010 Apr 1;100 Suppl 1:S216-23
pubmed: 19762673
Am J Public Health. 2003 May;93(5):792-7
pubmed: 12721146
BMC Psychiatry. 2018 Mar 12;18(1):65
pubmed: 29530018
Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):841-53
pubmed: 15386709
Fam Process. 2006 Jun;45(2):153-69
pubmed: 16768016
Stat Med. 2009 Mar 15;28(6):937-55
pubmed: 19153970
J Adolesc Health. 2014 Jul;55(1):85-92
pubmed: 24518532
Health Serv Res. 2012 Oct;47(5):2031-59
pubmed: 22417169
Eval Rev. 2005 Dec;29(6):530-58
pubmed: 16244051
J Urban Health. 2023 Apr;100(2):227-244
pubmed: 37037977
Soc Sci Med. 2008 Sep;67(6):947-55
pubmed: 18573582
Soc Sci Med. 2021 Oct;287:114374
pubmed: 34534779
Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):855-7
pubmed: 15386710
Am J Public Health. 2003 Feb;93(2):277-84
pubmed: 12554585
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
Stat Methods Med Res. 2007 Apr;16(2):167-84
pubmed: 17484299
Soc Sci Med. 2018 Feb;199:181-188
pubmed: 28342562
AIDS Care. 2015;27(10):1231-40
pubmed: 26213142
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
AIDS. 2005 Sep 23;19(14):1501-8
pubmed: 16135904
BMC Public Health. 2016 Feb 25;16:188
pubmed: 26911510
Am J Public Health. 2010 Apr 1;100 Suppl 1:S30-5
pubmed: 20147679
Ann Clin Psychiatry. 2017 Nov;29(4):227-234A
pubmed: 29069107
Soc Sci Med. 2016 May;157:127-37
pubmed: 27085071
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25316
pubmed: 31328425
J Adolesc Health. 2014 Jun;54(6):663-71
pubmed: 24702839
Am J Public Health. 2010 Apr 1;100 Suppl 1:S186-96
pubmed: 20147693
Science. 2015 May 15;348(6236):1260799
pubmed: 25977558